Why Gilead Sciences Remains A Buy After A 40% Rally
Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...
hdfncompanion2d
Rare Disease Day 2025: 10 recent FDA approvals for rare diseases
In honor of Rare Disease Day, here are 10 new treatments approved by the FDA to treat rare diseases over the past year.
Daily5d
Gilead Seladelpar gets Conditional European Marketing Authorization for Primary Biliary Cholangitis
Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...